Seres Therapeutics
MCRB
77 hedge funds and large institutions have $242M invested in Seres Therapeutics in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 9 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 24
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
6% more capital invested
Capital invested by funds: $227M → $242M (+$14.5M)
0.06% more ownership
Funds ownership: 4.71% → 4.76% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less funds holding
Funds holding: 79 → 77 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.61M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.12M |
| 3 |
JP Morgan Chase
New York
|
+$1.69M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$609K |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$487K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.17M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$741K |
| 3 |
Squarepoint
New York
|
-$730K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$494K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$406K |
MCRB Hedge Fund Activity: Q1 2020 in Review
77 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2020, worth a combined $242M — up 6.4% from $227M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MCRB positions and 9 closed out — a net gain of 1 holder — while 27 added to existing stakes and 24 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $4.61M. The largest seller was Fidelity Investments, cutting an estimated $1.17M.
- 77 institutional investors held Seres Therapeutics (MCRB) as of Q1 2020, down from 79 in Q4 2019.
- Funds reported $242M of Seres Therapeutics stock for Q1 2020, up 6.4% quarter-over-quarter.
- 10 funds opened new Seres Therapeutics positions in Q1 2020 and 9 closed out, a net change of +1 holder.
- The largest Seres Therapeutics buyer in Q1 2020 was ARK Investment Management, an estimated $4.61M added.
- The largest Seres Therapeutics seller in Q1 2020 was Fidelity Investments, an estimated $1.17M sold.
Based on aggregated 13F filings for Q1 2020.